Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660047 | 0.91 | HPGD (0.48) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2653282 | 0.88 | HPGD (0.46) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2653480 | 0.87 | HPGD (0.48) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2653095 | 0.86 | FGFR1 (0.47) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL5929894 | 0.86 | HPGD (0.53) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2653515 | 0.84 | HPGD (0.43) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2655066 | 0.81 | HPGD (0.45) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2653121 | 0.80 | FGFR1 (0.43) | HPGDFGFR1ALDH1A1KDR | |
| SCHEMBL2660005 | 0.79 | HPGD (0.48) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2660361 | 0.78 | HPGD (0.48) | HPGDFGFR1ALDH1A1NPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | claimed |
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1613618-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | GABRB2, GABRB1, GABRB3 | HPGD 2466/4885FGFR1 3374/4885ALDH1A1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.